Know Cancer

forgot password

1)Mixed Chimerism to Treat Sickle Cell Disease: Extended Protocol 2)Mixed Chimerism to Treat Non-Malignant Disorders of the Hematopoietic Stem Cell 3)Transplantation of Allogeneic Bone Marrow Enriched for Graft Facilitating Cells in the Treatment of Aplastic Anemia

Phase 1/Phase 2
Not Enrolling
Sickle Cell Disease

Thank you

Trial Information

1)Mixed Chimerism to Treat Sickle Cell Disease: Extended Protocol 2)Mixed Chimerism to Treat Non-Malignant Disorders of the Hematopoietic Stem Cell 3)Transplantation of Allogeneic Bone Marrow Enriched for Graft Facilitating Cells in the Treatment of Aplastic Anemia

Hematopoietic stem cell transplantation (HSCT) is emerging as a therapeutic alternative for
patients with sickle cell disease. Conventional HSCT therapy has been limited to extremely
high-risk hemoglobinopathy patients. Those patients who may be difficult to identify before
end-organ damage develops.

Also, conventional HSCT is only available to the minority of candidates who have
Histocompatibility Leukocyte Antigen (HLA) identical siblings to donate bone marrow or
mobilized peripheral blood stem cells.

This study proposes two important improvements over conventional HSCT:

- Donor peripheral blood or bone marrow will be processed via a new technology, which
will deplete mature immune cells while enriching hematopoietic stem cells (HSC) and
graft facilitating cells (FC).

- A reduced intensity recipient conditioning regimen will be used to promote mixed
allogeneic chimerism, as opposed to full donor chimerism, following HSCT.

These two elements may significantly improve the benefit:risk ratio of HSCT for patients
with hemoglobinopathies. Stem cell transplantation may become a more feasible option for
patients that do not have HLA-identical siblings that can donate stem cells. Also,
transplantation may be offered to patients earlier in the disease progression, before
end-organ damage occurs.

Inclusion Criteria:

The following criteria are established to identify subjects with sickle cell disease (SCD)
who have a high predicted morbidity and are at risk for early mortality. Subjects with
S/S disease, S/C disease, Hemoglobin H disease, Alpha Thalassemia Major, Thalassemia Major
(also known as Cooley's anemia) or S/B* thalassemia and one or more of the following
medical complications will be eligible:

- History of impaired neurological function and/or findings on Magnetic Resonance Image
(MRI)/Magnetic Resonance Angiogram (MRA) that are associated with sickle cell disease

- More than 1 episode of acute chest syndrome with stage I or II pulmonary disease

- Osteonecrosis involving ≥ 2 joints

- Sickle cell nephropathy as evidenced by a glomerular filtration rate of 30% - 50% of
the predicted normal

- Alloimmunization that is sufficient to interfere with the efficacy of chronic
transfusion therapy

- Chronic or recurrent priapism

- Major visual impairment in one or both eyes with bilateral proliferative retinopathy

- Persistent disabling pain (≥ 2 episodes per year) despite trials of chronic
transfusion and/or hydroxyurea at recommended doses for at least 6 months duration

Additional General Criteria:

Subjects must also meet all of the following general inclusion criteria:

- Subjects must have a related donor (identical or mismatched for 1, 2 or 3 HLA- A,
HLA-B or HLA-DR loci).

- Subjects must have adequate cardiopulmonary function as documented by a left
ventricular ejection fraction ≥ 50% (or within normal limits per Institutional
criteria) or a left ventricular shortening fraction Within normal limits (WNL) per
Institutional criteria, without inotropic support. If Ejection fraction is 40-50%,
the patient may be considered for participation if cleared by a Cardiologist.

- Subjects must have adequate pulmonary function as documented by Diffusing capacity of
the lung for carbon monoxide (DLCO) and Forced expiratory volume in 1 second (FEV1)

- 50% predicted for age and size. If DLCO and FEV1 are between 40-50%, patient
may be considered for participation if cleared by a Pulmonologist.

- Subjects must have adequate hepatic function as demonstrated by a serum albumin ≥ 3.0
mg/dL, and serum glutamic pyruvic transaminase (SGPT) or serum glutamic oxaloacetic
transaminase (SGOT) ≤ 2.5 times the upper limit of normal.

- Subjects must have adequate renal function as demonstrated by a serum creatinine ≤
1.5 mg/dL. If serum creatinine is ≥ 1.5 mg/dL, then a creatinine clearance test must
be done and the result 50% of normal.

- Subjects or legal guardians must give written informed consent, and subjects must
assent where age and intellectually appropriate.

- There are no age limits for this protocol.

Exclusion Criteria:

- Uncontrolled infection or severe concomitant diseases, which in the judgment of the
Principal Investigator, could not tolerate transplantation.

- Severe impairment of functional performance as evidenced by a Karnofsky (patients ≥16
years old) or Lansky (children <16 years old) score <70%

- Stage III or IV sickle cell pulmonary disease

- Renal insufficiency (GFR < 25% of predicted normal for age)

- Subjects with a positive human immunodeficiency virus (HIV) antibody test result

- Subjects who are pregnant, as indicated by a positive serum human chorionic
gonadotrophin (HCG) test

- Subjects of childbearing potential who are not practicing adequate contraception as
defined by the investigator at the site

- Subjects must not have had previous radiation therapy that would preclude total body
irradiation (as determined by a radiation oncologist).

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Level of Donor Chimerism from Enriched Hematopoietic Stem Cell Engraftment

Outcome Description:

Tests are done at key time points to monitor for donor chimerism by evaluating presence of bone marrow-derived hematopoietic stem cells.

Outcome Time Frame:

From one month to three years

Safety Issue:


Principal Investigator

Roger Herzig, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

James Graham Brown Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

January 2005

Completion Date:

April 2012

Related Keywords:

  • Sickle Cell Disease
  • Sickle Cell
  • Stem Cell
  • Tolerance
  • Bone Marrow Transplant
  • Total Body Irradiation (TBI)
  • Apheresis
  • Aplastic Anemia
  • Hemoglobinopathies
  • Non Malignant
  • Anemia, Aplastic
  • Anemia, Sickle Cell
  • Hemoglobinopathies



St. Christopher's Hospital for ChildrenPhiladelphia, Pennsylvania  19134-1095
Duke University Medical CenterDurham, North Carolina  27710
University of LouisvilleLouisville, Kentucky  40202